Screener
ImmunityBio, Inc. IBRX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Due to and due from related parties, net | 570 | 51 |
| Operating lease liabilities | (992) | (916) |
| Operating lease liabilities – related parties | (938) | (816) |
| Net cash used in operating activities | (75,359) | (85,905) |
| Investing activities: | ||
| Purchases of marketable debt securities, available-for-sale | (139,093) | (100) |
| Proceeds from maturities of marketable debt securities, available-for-sale | 79,382 | 5,350 |
| Proceeds from sales of marketable debt securities, available-for-sale | 39,848 | — |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s operating cash flow?
- ImmunityBio, Inc. (IBRX) reported operating cash flow of -$75.36M in Q1 2026.
- How has ImmunityBio, Inc.'s operating cash flow changed year-over-year?
- ImmunityBio, Inc.'s operating cash flow increased by 12.3% year-over-year, from -$85.91M to -$75.36M.
- What is the long-term trend for ImmunityBio, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s operating cash flow has grown at a 2.7% compound annual growth rate (CAGR), from -$274.42M to -$304.94M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about ImmunityBio, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude